We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

Published: March 2018
Pages: 277
Code: 369FAF8923F83F6429CE91F81D7BD091
Format: PDF
Publisher GlobalData
From Add to basket
$ 2,500.00
GlobalData's clinical trial report, “ provides an overview of Non-Alcoholic Steatohepatitis (NASH) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Additonal Information

  • - The report provides a snapshot of the global clinical trials landscape
  • - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • - The Report provides enrollment trends for the past five years
  • - Report provides latest news for the past three months
  • *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Gilead Sciences Inc
Pfizer Inc
Novartis AG
Allergan Plc
Conatus Pharmaceuticals Inc
Bristol-Myers Squibb Co
Genextra Spa
WCCT Global Inc
Genfit SA
Galmed International Ltd

Reasons to buy

Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Add to basket
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Report Guidance 7
  • GlobalData Clinical Trials Report Coverage 8
  • Clinical Trials by Region 9
  • Clinical Trials and Average Enrollment by Country 10
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
  • Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials 30
  • Prominent Drugs 31
  • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis (NASH) 32
  • Apr 09, 2018: Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018 32
  • Apr 09, 2018: Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL) 32
  • Apr 05, 2018: Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April 32
  • Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018 33
  • Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial 33
  • Apr 01, 2018: MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis 34
  • Mar 28, 2018: GENFIT: Presentations at EASL 2018 Annual Congress Highlight Progress in NASH Diagnostics, Combination Therapies and Deep-learning Applications in Medical Imaging 34
  • Mar 28, 2018: Enanta Pharmaceuticals Announces Poster Presentations on EDP-305 at ICL 2018 35
  • Mar 28, 2018: Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors 35
  • Mar 27, 2018: Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL 36
  • Mar 23, 2018: Intercept Announces Multiple New Ocaliva (obeticholic acid) Data Presentations at the International Liver Congress 2018 36
  • Mar 14, 2018: Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference 37
  • Mar 12, 2018: NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018 37
  • Mar 12, 2018: Immuron Commences US Non-Deal Institutional Investor Roadshow 38
  • Mar 08, 2018: Immuron Reports Positive Results in NASH Clinical Trial 38
  • Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference 40
  • Mar 08, 2018: Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease 40
  • Mar 07, 2018: Gencia Will Present Preclinical Results in the DIAMOND Mice Supporting the Therapeutic Potential of Its Lead Mitochondrial Therapeutic, GEN-3026, to Treat NASH at the International Liver Congress 41
  • Mar 07, 2018: Cerenis Therapeutics Announces Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD 41
  • Mar 06, 2018: Can-Fite to Provide Update on Liver Drug Namodenoson at the 30th Annual ROTH Conference 42
  • Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences 42
  • Mar 05, 2018: Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer 42
  • Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson 43
  • Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities 43
  • Feb 14, 2018: Galmed Announces ARRIVE Study Data 43
  • Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson 44
  • Feb 12, 2018: Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis 44
  • Feb 05, 2018: NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC) 45
  • Jan 30, 2018: Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress 2018 45
  • Jan 28, 2018: MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France 46
  • Jan 23, 2018: GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA 46
  • Clinical Trial Profile Snapshots 48
  • Appendix 275
  • Abbreviations 275
  • Definitions 275
  • Research Methodology 276
  • Secondary Research 276
  • About GlobalData 277
  • Contact Us 277
  • Source 277
  • List of Tables
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region, 2018* 9
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 12
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries, 2018* 14
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 15
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 16
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018* 17
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018* 20
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase, 2018* 23
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 24
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 28
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31
  • List of Figures
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region (%), 2018* 9
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 12
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 14
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 15
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 16
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018* 17
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018* 20
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 23
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 24
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 28
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
  • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31
  • GlobalData Methodology 276

Keywords
;